Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.25
Bid: 14.00
Ask: 14.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.571%)
Open: 14.25
High: 14.25
Low: 14.00
Prev. Close: 14.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Synature Ltd

15 Nov 2005 07:03

Angle PLC15 November 2005 For immediate release 15 November 2005 ANGLE plc ("ANGLE") SENIOR APPOINTMENTS AND VENTURE UPDATE ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce two senior appointments at its venture company, SynatureLtd. Founded earlier this year, Synature Ltd (formerly known as Customiser Group Ltd)provides psychological profiling tools that engage the consumer, deliveringinsight into individual attitudes and consumer preferences complementingtraditional demographic models. Based in Guildford Surrey, Synature Ltd is oneof ANGLE's eight venture companies. Dr. John Woods joins Synature Ltd as Chief Executive Officer. Previously founderand Chief Executive of Site Intelligence Ltd, one of the UK's most successfulweb analytics companies, John has worked with clients such as Argos, Expedia,SAP and Lloyds TSB. Dr. Woods has 15 years' experience in commercialisation and marketing ofadvanced software technologies. He holds a doctorate from Jesus College, Oxfordand an MBA. Commenting on his appointment, Dr. Woods said "I am delighted to be joining the Synature team at this exciting stage in thecompany's development. Marketing departments have a growing appetite forenhanced profiling and targeting of online and offline customers. Synature'sunique intellectual property offers a compelling way to meet that need.Moreover, ANGLE provides Synature with a supportive environment in which thatcompelling intellectual property can be rapidly and successfully commercialised." Professor William J. Fitzgerald joins Synature Ltd as a consultant technicaladvisor. He is Professor of Applied Statistics and Signal Processing and Headof the Signal Processing and Communications Laboratory at the University ofCambridge. He consults for a number of successful high technology companies inboth the UK and USA. Professor Fitzgerald commented: "Synature's consumer profiling techniques demonstrate the real world businessbenefits that can be obtained from state-of-the-art data analysis and patternrecognition. I am excited to be part of the team and to be ensuring thatSynature's clients receive maximum insight and maximum value from theapplication of our technologies." Stephen Bence, Director of New Ventures at ANGLE, added: "These two key appointments complement Synature's existing founding team andprovide the company with additional commercial and technical expertise. We areexcited about the opportunity that Synature's unique intellectual propertyrepresents." For further information ANGLE plc 01483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Synature Ltd 08701 909550John Woods, Chief Executive Buchanan Communications 020 7466 5000Richard Darby, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com Synature Ltd is an ANGLE Technology group company formed to commercialiseintellectual property acquired in 2005 from Customiser Ltd. Synature'sintellectual property provides unique ways to profile consumers in terms oftheir underlying preferences. The resulting profiles allow fine-grainedconsumer segmentation that complements traditional demographics. Synature'stechniques can be applied both online and offline. Further information can be found on www.synature.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.